Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Itovebi
(inavolisib)
Uses, side effects, dosage information & price range
About this medicine
Itovebi, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment (see section 5.1). Patients previously treated with a CDK 4/6 inhibitor in the (neo)adjuvant setting should have had an interval of at least 12 months between termination of CDK 4/6 inhibitor treatment and the detection of recurrence. In pre/perimenopausal women and in men, endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
inavolisib
Category
Antineoplastic agents;Protein kinase inhibitors
Manufacturer
Roche Registration GmbH
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.